Literature DB >> 16956585

NF-kappaB in solid tumors.

Francesco Pacifico1, Antonio Leonardi.   

Abstract

Cancer is a multistep process during which cells acquire genetic alterations that drive the progressive transformation of normal cells into highly malignant cells. Self-sufficiency in growth, insensitivity to anti-growth signals, evasion of apoptosis, limitless replicative potential, sustained angiogenesis, tissue invasion and metastasis, are signatures of transformed cells. NF-kappaB is a key actor in tumorigenesis given its ability to control the expression and the function of a number of genes involved in these processes. Indeed, constitutive activation of NF-kappaB is a common feature of many human tumors, while its sustained activation during inflammation predisposes normal cells to neoplastic transformation. Since suppression of NF-kappaB has been shown to inhibit oncogenic potential of transformed cells, targeting it should be effective in the prevention and treatment of cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16956585     DOI: 10.1016/j.bcp.2006.07.032

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  65 in total

1.  Characterization and mechanistic studies of a novel melanoma-targeting construct containing IκBa for specific inhibition of nuclear factor-κB activity.

Authors:  Hong Zhou; Yuying Liu; Lawrence H Cheung; Sehoon Kim; Weihe Zhang; Khalid A Mohamedali; Preetha Anand; Walter N Hittelman; Bharat B Aggarwal; Michael G Rosenblum
Journal:  Neoplasia       Date:  2010-10       Impact factor: 5.715

2.  PAX7-FKHR fusion gene inhibits myogenic differentiation via NF-kappaB upregulation.

Authors:  Elizabeth Charytonowicz; Igor Matushansky; Josep Domingo Doménech; Mireia Castillo-Martín; Marc Ladanyi; Carlos Cordon-Cardo; Mel Ziman
Journal:  Clin Transl Oncol       Date:  2012-03       Impact factor: 3.405

Review 3.  Targeting inflammatory pathways for tumor radiosensitization.

Authors:  Amit Deorukhkar; Sunil Krishnan
Journal:  Biochem Pharmacol       Date:  2010-06-30       Impact factor: 5.858

4.  Anti-rheumatic drug iguratimod (T-614) alleviates cancer-induced bone destruction via down-regulating interleukin-6 production in a nuclear factor-κB-dependent manner.

Authors:  Yue Sun; Da-Wei Ye; Peng Zhang; Ying-Xing Wu; Bang-Yan Wang; Guang Peng; Shi-Ying Yu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2016-10-18

5.  Inhibition of IkB kinase and NF-kappaB by a novel synthetic compound SK 2009.

Authors:  Ravi Kumar Anchoori; Kuzhuvelil B Harikumar; Venkateswara Rao Batchu; Bharat B Aggarwal; Saeed R Khan
Journal:  Bioorg Med Chem       Date:  2009-11-04       Impact factor: 3.641

6.  Inhibition of nuclear factor-kappa B differentially affects thyroid cancer cell growth, apoptosis, and invasion.

Authors:  Kevin T Bauerle; Rebecca E Schweppe; Bryan R Haugen
Journal:  Mol Cancer       Date:  2010-05-21       Impact factor: 27.401

7.  Nuclear factor-κB expression is predictive of overall survival in patients with cutaneous melanoma.

Authors:  Daniela Murtas; Franca Piras; Luigi Minerba; Jorge Ugalde; Michela Piga; Cristina Maxia; Maria Teresa Perra; Paola Sirigu
Journal:  Oncol Lett       Date:  2010-07-01       Impact factor: 2.967

8.  The nuclear factor-kappaB pathway controls the progression of prostate cancer to androgen-independent growth.

Authors:  Ren Jie Jin; Yongsoo Lho; Linda Connelly; Yongqing Wang; Xiuping Yu; Leshana Saint Jean; Thomas C Case; Katharine Ellwood-Yen; Charles L Sawyers; Neil A Bhowmick; Timothy S Blackwell; Fiona E Yull; Robert J Matusik
Journal:  Cancer Res       Date:  2008-08-15       Impact factor: 12.701

9.  Ginger extract (Zingiber officinale) has anti-cancer and anti-inflammatory effects on ethionine-induced hepatoma rats.

Authors:  Shafina Hanim Mohd Habib; Suzana Makpol; Noor Aini Abdul Hamid; Srijit Das; Wan Zurinah Wan Ngah; Yasmin Anum Mohd Yusof
Journal:  Clinics (Sao Paulo)       Date:  2008-12       Impact factor: 2.365

10.  Glycogen synthase kinase-3 inhibition disrupts nuclear factor-kappaB activity in pancreatic cancer, but fails to sensitize to gemcitabine chemotherapy.

Authors:  Shadi Mamaghani; Satish Patel; David W Hedley
Journal:  BMC Cancer       Date:  2009-04-30       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.